Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...
Use of the antifibrinolytic medication ‘narrowly exceeded’ noninferiority in VTE risk compared with placebo in noncardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results